Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: Guidelines from the European Association for Neuro-Oncology

The Lancet Oncology

Volumn 16, Issue 7, 2015, Pages e322-e332

  Hoang Xuan, Khê ^a   Bessell, Eric ^b   Bromberg, Jacoline ^c   Hottinger, Andreas F ^d   Preusser, Matthias ^e   Rudà, Roberta ^f   Schlegel, Uwe ^g   Siegal, Tali ^h   Soussain, Carole ^i,j   Abacioglu, Ufuk ^k   Cassoux, Nathalie ⁱ   Deckert, Martina ^l   Dirven, Clemens M F ^c   Ferreri, Andrés J M ^m   Graus, Francesc ⁿ   Henriksson, Roger ^o,t   Herrlinger, Ulrich ^p   Taphoorn, Martin ^q,r   Soffietti, Riccardo ^f   Weller, Michael ^s  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f UNIVERSITY OF TURIN   (Italy)

^g RUHR UNIVERSITY BOCHUM   (Germany)

^h RABIN MEDICAL CENTER   (Israel)

ⁱ INSTITUT CURIE   (France)

^j CNRS   (France)

^k Radiation Oncology Department Neolife Medical Center   (Turkey)

^l UNIVERSITY OF COLOGNE   (Germany)

^m SAN RAFFAELE HOSPITAL   (Italy)

ⁿ HOSPITAL CLÍNIC   (Spain)

^o Regional Cancer Center Stockholm Gotland   (Sweden)

^p UNIVERSITY HOSPITAL BONN   (Germany)

^q MEDICAL CENTER HAAGLANDEN   (Netherlands)

^r VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^s UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^t UMEÅ UNIVERSITY   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENDAMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LOMUSTINE; METHOTREXATE; PEMETREXED; PREDNISOLONE; PROCARBAZINE; RITUXIMAB; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN RADIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; CONSENSUS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELDERLY CARE; HUMAN; IMMUNOCOMPETENCE; MEDICAL SOCIETY; MONOTHERAPY; MYELOABLATIVE CONDITIONING; NEPHROTOXICITY; PRACTICE GUIDELINE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SALVAGE THERAPY; SYSTEMIC THERAPY; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AUTOTRANSPLANTATION; CENTRAL NERVOUS SYSTEM NEOPLASMS; EUROPE; EVIDENCE BASED MEDICINE; FEMALE; IMMUNOLOGY; LYMPHOMA; MALE; MORTALITY; MULTIMODALITY CANCER THERAPY; NEUROSURGERY; PATHOLOGY; PROCEDURES; PROGNOSIS; STANDARDS; STEM CELL TRANSPLANTATION; SURVIVAL; TUMOR INVASION;

CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; EUROPE; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; IMMUNOCOMPETENCE; LYMPHOMA; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEUROSURGICAL PROCEDURES; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RADIOTHERAPY, ADJUVANT; SOCIETIES, MEDICAL; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84937440406     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00076-5     Document Type: Review

References (100)

1. Kluin PM, Deckert M, Ferry JA Primary diffuse large B-cell lymphoma of the CNS. World Health Organization classification of tumours pathology and genetics of tumours of the haematopoietic and lymphoid tissues 2008, 240-241. IARC Press, Lyon. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
2. Kadan-Lottick NS, Skluzacek MC, Gurney JG Decreasing incidence rates of primary central nervous system lymphoma. Cancer 2002, 95:193-202.
3. Bessell EM, Dickinson P, Dickinson S, et al. Increasing age at diagnosis and worsening renal function in patients with primary central nervous system lymphoma. J Neurooncol 2011, 104:191-193.
4. Villano JL, Koshy M, Shaikh H, et al. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 2011, 105:1414-1418.
5. O'Neill BP, Decker PA, Tieu C, et al. The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin's lymphoma. Am J Hematol 2013, 88:997-1000.
6. Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009, 374:1512-1520.
7. Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 2010, 11:1036-1047.
8. Omuro AM, Chinot O, Taillandier L, et al. Methotrexate and temozolomide versus methotreaxate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in the elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol 2015, 2:e251-e259.
9. Henry JM, Heffner RR, Dillard SH, et al. Primary malignant lymphomas of the central nervous system. Cancer 1974, 34:1293-1302.
10. Bataille B, Delwail V, Menet E, et al. Primary intracerebral malignant lymphoma: a report of 248 cases. J Neurosurg 2000, 92:261-266.
11. Bellinzona M, Roser F, Ostertag H, et al. Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases. Eur J Surg Oncol 2005, 31:100-105.
12. Lai R, Rosenblum MK, DeAngelis LM Primary CNS lymphoma: a whole-brain disease?. Neurology 2002, 59:1557-1562.
13. Weller M, Martus P, Roth P, et al. Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro Oncol 2012, 14:1481-1484.
14. O'Neill BP, O'Fallon JR, Earle JD, et al. Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy?. Int J Radiat Oncol Biol Phys 1995, 33:663-673.
15. Schultz C, Scott C, Sherman W, et al. Pre-irradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone (CHOD) for PCNSL: initial report of Radiation Therapy Oncology Group (RTOG) protocol 88-06. J Clin Oncol 1996, 14:556-564.
16. Mead GM, Bleehen NM, Gregor A, et al. A Medical Research Council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer 2000, 89:1359-1370.
17. Hiraga S, Arita N, Ohnishi T, et al. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into CSF and intensified tumour response in PCNSL. J Neurosurg 1999, 91:221-230.
18. Glass J, Gruber ML, Cher L, et al. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 1994, 81:188-195.
19. Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol 2013, 31:3971-3979.
20. Herrlinger U, Schabet M, Brugger W, et al. German Cancer Society Neuro-Oncology Working Group NOA-03 multicentre trial of single agent high dose methotrexate for primary CNS lymphoma. Ann Neurol 2002, 51:247-252.
21. Batchelor T, Carson K, O'Neill A, et al. Treatment of primary cerebral lymphoma with methotrexate and deferred radiotherapy: report of NABTT 96-07. J Clin Oncol 2003, 21:1044-1049.
22. Bergner N, Monsef I, Illerhaus G, et al. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL). Cochrane Database Syst Rev 2012, 11. CD009355.
23. Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 2013, 31:3061-3068.
24. Ferreri AJ, Licata G, Foppoli M, et al. Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination. Oncologist 2011, 16:336-341.
25. Slevin ML, Piall EM, Aherne GW, et al. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol 1983, 1:546-551.
26. Neuwelt EA, Goldman DL, Dahlborg SA, et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 1991, 9:1580-1590.
27. McAllister LD, Doolittle ND, Guastadisegni PE, et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000, 46:51-60.
28. Angelov L, Doolittle ND, Kraemer DF, et al. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J Clin Oncol 2009, 27:3503-3509.
29. Ferreri AJ, Ciceri F, Brandes AA, et al. MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years. Neurology 2014, 82:1370-1373.
30. Ferreri AJ, Reni M, Pasini F, et al. Multicenter study of treatment of primary CNS lymphoma. Neurology 2002, 58:1513-1520.
31. Khan RB, Shi W, Thaler HT Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?. J Neurooncol 2002, 58:175-178.
32. Sierra Del Rio M, Ricard D, Houillier C, et al. Prophylactic intrathecal chemotherapy in primary CNS lymphoma. J Neurooncol 2012, 106:143-146.
33. Pels H, Schmidt-Wolf IG, Glasmacher A, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003, 21:4489-4495.
34. Pels H, Juergens A, Glasmacher A, et al. Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. J Neurooncol 2009, 91:299-305.
35. Batchelor TT, Grossman SA, Mikkelsen T, et al. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology 2011, 76:929-930.
36. Chamberlain MC, Johnston SK High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. Neuro Oncol 2010, 12:736-744.
37. Fritsch K, Kasenda B, Hader C, et al. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol 2011, 22:2080-2085.
38. Mappa S, Marturano E, Licata G, et al. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. Hematol Oncol 2013, 31:143-150.
39. Nayak L, Abrey LE, Drappatz J, et al. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leuk Lymphoma 2013, 54:58-61.
40. Birnbaum T, Stadler EA, von Baumgarten L, et al. Rituximab significantly improves complete response rate in patients with primary CNS lymphoma. J Neurooncol 2012, 109:285-291.
41. Gregory G, Arumugaswamy A, Leung T, et al. Rituximab is associated with improved survival for aggressive B cell CNS lymphoma. Neuro Oncol 2013, 15:1068-1073.
42. Holdhoff M, Ambady P, Abdelaziz A, et al. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology 2014, 83:235-239.
43. Rubenstein JL, Li J, Chen L, et al. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood 2013, 121:745-751.
44. Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992, 23:9-17.
45. DeAngelis LM, Yahalom J, Thaler HT, et al. Combined modality treatment for primary central nervous system lymphoma. J Clin Oncol 1992, 10:635-643.
46. Blay JY, Bouhour D, Carrie C, et al. The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression. Blood 1995, 86:2922-2929.
47. O'Brien P, Roos D, Pratt G, et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 2000, 18:519-526.
48. Omuro AM, DeAngelis LM, Yahalom J, et al. Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology 2005, 64:69-74.
49. Abrey LE, Yahalom J, De Angelis L Treatment of primary CNS lymphoma: the next step. J Clin Oncol 2000, 18:3144-3150.
50. Bessell EM, Graus F, Lopez-Guillermo A, et al. CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkins lymphoma. Int J Radiat Oncol Biol Phys 2003, 50:457-464.
51. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 2003, 21:4483-4488.
52. Gavrilovic IT, Hormigo A, Yahalom J, et al. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 2006, 24:4570-4574.
53. Ghesquieres H, Ferlay C, Sebban C, et al. Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Ann Oncol 2010, 21:842-850.
54. Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol 2011, 100:86-92.
55. DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002, 20:4643-4648.
56. Ferreri AJ, DeAngelis L, Illerhaus G, et al. Whole-brain radiotherapy in primary CNS lymphoma. Lancet Oncol 2011, 12:118-119.
57. Weller M The vanishing role of whole brain radiotherapy in primary central nervous system lymphoma. Neuro Oncol 2014, 16:1035-1036.
58. DeAngelis LM Whither whole brain radiotherapy for primary CNS lymphoma?. Neuro Oncol 2014, 16:1032-1034.
59. Zacher J, Kasenda B, Enger A, et al. The role of additional radiotherapy for primary central nervous system lymphoma. Cochrane Database Syst Rev 2014, 6. CD009211.
60. Omuro AM, Taillandier L, Chinot O, et al. Methotrexate (MTX), procarbazine and CCNU for primary central nervous system lymphoma (PCNSL) in patients younger than 60: can radiotherapy (RT) be deferred?. J Neurooncol 2006, 104:323-330.
61. Ekenel M, Iwamoto FM, Ben-Porat LS, et al. Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy. Cancer 2008, 113:1025-1031.
62. Jürgens A, Pels H, Rogowski S, et al. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol 2010, 67:182-189.
63. Sandor V, Stark-Vancs V, Pearson D, et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 1998, 16:3000-3006.
64. Hoang-Xuan K, Taillandier L, Chinot O, et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 2003, 21:2726-2731.
65. Bessell EM, Lopez-Guillermo A, Villa S, et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: An analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 2002, 20:231-236.
66. Ferreri AJ, Verona C, Politi L, et al. Consolidation radiotherapy in primary CNS lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy. Int J Radiat Oncol Biol Phys 2011, 80:169-175.
67. Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol 2008, 26:2512-2518.
68. Soussain C, Choquet S, Fourme E, et al. Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary CNS and intraocular lymphoma: a retrospective study of 79 cases. Haematologica 2012, 97:1751-1756.
69. Welch MR, Sauter CS, Matasar MJ, et al. Autologous stem cell transplant in recurrent or refractory primary or secondary CNS lymphoma using thiotepa, busulfan and cyclophosphamide (TBC). Leuk Lymphoma 2015, 56:361-367.
70. Colombat P, Lemevel A, Bertrand P, et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 2006, 38:417-420.
71. Illerhaus G, Marks R, Ihorst G, et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006, 24:3865-3870.
72. Abrey LE, Moskowitz CH, Mason WP, et al. Intensive methotrexate and cytarabine followed by high dose chemotherapy with autologous stem cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent to treat analysis. J Clin Oncol 2003, 21:4151-4156.
73. Alimohamed N, Daly A, Owen C, et al. Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience. Leuk Lymphoma 2012, 53:862-867.
74. Illerhaus G, Müller F, Feuerhake F, et al. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 2008, 93:147-148.
75. Kiefer T, Hirt C, Späth C, et al. Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamatologie und Onkologie OSHO-53 phase II study. Ann Oncol 2012, 23:1809-1812. for the Ostdeutsche Studiengruppe Hämatologie und Onkologie.
76. Schorb E, Kasenda B, Atta J, et al. Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. Haematologica 2013, 98:765-770.
77. Illerhaus G, Marks R, Muller F, et al. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol 2009, 20:319-325.
78. Laack NN, Ballman KV, Brown PB, et al. Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51. Int J Radiat Oncol Biol Phys 2006, 65:1429-1439.
79. Roth P, Martus P, Kiewe P, et al. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial. Neurology 2012, 79:890-896.
80. Omuro AM, Taillandier L, Chinot O, et al. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 2007, 85:207-211.
81. Ney DE, Reiner AS, Panageas KS, et al. Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Cancer 2010, 116:4605-4612.
82. Schuurmans M, Bromberg JE, Doorduijn J, et al. Primary central nervous system lymphoma in the elderly: a multicentre retrospective analysis. Br J Haematol 2010, 151:179-184.
83. Taoka K, Okoshi Y, Sakamoto N, et al. A non radiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma. Int J Hematol 2010, 92:617-623.
84. Zhu JJ, Gerstner ER, Engler DA, et al. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol 2009, 11:211-215.
85. Kurzwelly D, Glas M, Roth P, et al. Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. J Neurooncol 2010, 97:389-392.
86. Welch MR, Omuro A, DeAngelis LM Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center. Neuro Oncol 2012, 14:1304-1311.
87. Jahnke K, Korfel A, Martus P, et al. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol 2005, 16:445-449. for the German Primary Central Nervous System Lymphoma Study Group (G-PCNSL-SG).
88. Correa DD, Shi W, Abrey LE, et al. Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro Oncol 2012, 14:101-108.
89. Hottinger AF, DeAngelis LM, Yahalom J, et al. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology 2007, 69:1178-1182.
90. Nguyen PL, Chakravarti A, Finkelstein DM, et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 2005, 23:1507-1513.
91. Reni M, Zaja F, Mason W, et al. Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 2007, 96:864-867.
92. Fischer L, Thiel E, Klasen HA, et al. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol 2006, 17:1141-1145.
93. Raizer JJ, Rademaker A, Evens AM, et al. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. Cancer 2012, 118:3743-3748.
94. Chamberlain MC Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series. J Neurooncol 2014, 118:155-162.
95. Herrlinger U, Brugger W, Bamberg M, et al. PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology 2000, 54:1707-1708.
96. Arellano-Rodrigo E, Lopez-Guillermo A, Bessell EM, et al. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol 2003, 70:219-224.
97. Sierra del Rio M, Choquet S, Hoang-Xuan K, et al. Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma. J Neurooncol 2011, 10:409-414.
98. Plotkin SR, Betensky RA, Hochberg FH, et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 2004, 10:5643-5646.
99. Pentsova E, Deangelis LM, Omuro A Methotrexate re-challenge for recurrent primary central nervous system lymphoma. J Neurooncol 2014, 117:161-165.
100. Provencher S, Ferlay C, Alaoui-Slimani K, et al. Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series. Hematol Oncol 2011, 29:10-16.